Gianfranco Delle Fave
Research Subjects
Gianfranco Delle Fave has a total of 397 co-authors. Here are the top co-authors by number of shared publications:
- Gabriele Capurso
Pancreatobiliary Endoscopy and Endosonography Division, IRCCS San Raffaele Scientific Institute, Italy
62 shared publications - Francesco Panzuto
Department of Medical-Surgical Sciences and Translational Medicine, Sapienza University of Rome, Digestive Disease Unit, ENETS Center of Excellence, Sant’Andrea University Hospital, Rome, Italy
29 shared publications Elettra Merola
Universitätsklinikum Erlangen
19 shared publications- Livia Archibugi
Pancreatico-Biliary Endoscopy and Endosonography Division, Pancreas Translational and Clinical Research Center, IRCCS San Raffaele Hospital, Milan, Italy
18 shared publications - Matteo Piciucchi
Digestive and Liver Disease Unit, S. Andrea Hospital, Faculty of Medicine and Psychology, Sapienza University of Rome, Italy
18 shared publications - Roberto Valente
Department of Diagnostics and Intervention, Surgery, Umeå University, 901 87 Umeå, Sweden
18 shared publications
Latest Publications
- Open Access
- 1 November 2025
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (11) , 1651
Lactobacillus rhamnosus GG Administration Is Associated with Stimulation of Vitamin D/VDR Pathway and Mucosal Microbiota Modulation in Ulcerative Colitis Patients: A Pilot Study
Background: The interaction between probiotics and the vitamin D/vitamin D receptor (VDR) pathway has been increasingly explored as a potential mechanism for immune modulation in inflammatory bowel disease (IBD). Lactobacillus rhamnosus GG (LGG) has shown promising results in ulcerative colitis (UC) patients, but its effect on the VDR pathway remains unexplored in humans. Aim: To test the hypothesis that LGG can stimulate the vitamin D/VDR pathway and modulate mucosal-adherent microbiota. Methods: In this study, we analyzed a subgroup of 13 patients from the LGGinUC trial, in which UC patients with mild-to-moderate disease activity received LGG monotherapy for four weeks. Colonic biopsy samples were collected before and after treatment to evaluate VDR expression via RT-qPCR and immunohistochemistry. Mucosal-adherent microbiota was also analyzed by DNA extraction and next-generation sequencing (NGS). Results: LGG administration significantly increased VDR mRNA expression in colonic mucosa (p < 0.05), with a corresponding rise in VDR protein levels in both epithelial and sub-epithelial compartments. Microbiota analysis revealed a reduction in α-diversity, primarily due to a decrease in commensal bacterial species, while β-diversity remained largely unchanged. Conclusions: Although the present results have to be considered preliminary, this is the first human study demonstrating that probiotic supplementation can upregulate VDR expression in colonic mucosa. We propose that LGG may exert its beneficial effects in UC by stimulating the VDR pathway, which in turn modulates mucosal immunity and microbiota composition. Further studies with larger sample sizes and longer treatment durations are needed to validate these findings and explore their therapeutic implications.
- 1 November 2025
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (11) , 1651
Open AccessLactobacillus rhamnosus GG Administration Is Associated with Stimulation of Vitamin D/VDR Pathway and Mucosal Microbiota Modulation in Ulcerative Colitis Patients: A Pilot Study
Background: The interaction between probiotics and the vitamin D/vitamin D receptor (VDR) pathway has been increasingly explored as a potential mechanism for immune modulation in inflammatory bowel disease (IBD). Lactobacillus rhamnosus GG (LGG) has shown promising results in ulcerative colitis (UC) patients, but its effect on the VDR pathway remains unexplored in humans. Aim: To test the hypothesis that LGG can stimulate the vitamin D/VDR pathway and modulate mucosal-adherent microbiota. Methods: In this study, we analyzed a subgroup of 13 patients from the LGGinUC trial, in which UC patients with mild-to-moderate disease activity received LGG monotherapy for four weeks. Colonic biopsy samples were collected before and after treatment to evaluate VDR expression via RT-qPCR and immunohistochemistry. Mucosal-adherent microbiota was also analyzed by DNA extraction and next-generation sequencing (NGS). Results: LGG administration significantly increased VDR mRNA expression in colonic mucosa (p < 0.05), with a corresponding rise in VDR protein levels in both epithelial and sub-epithelial compartments. Microbiota analysis revealed a reduction in α-diversity, primarily due to a decrease in commensal bacterial species, while β-diversity remained largely unchanged. Conclusions: Although the present results have to be considered preliminary, this is the first human study demonstrating that probiotic supplementation can upregulate VDR expression in colonic mucosa. We propose that LGG may exert its beneficial effects in UC by stimulating the VDR pathway, which in turn modulates mucosal immunity and microbiota composition. Further studies with larger sample sizes and longer treatment durations are needed to validate these findings and explore their therapeutic implications.
- 1 June 2018
- Published by Elsevier in Pancreatology
- Vol. 18 (4) , S146-S147
SLC22A3 polymorphisms may influence overall patient survival- PANDORA study
- 1 June 2018
- Published by Elsevier in Pancreatology
- Vol. 18 (4) , S146-S147
SLC22A3 polymorphisms may influence overall patient survival- PANDORA study
- 1 June 2018
- Published by Elsevier in Pancreatology
- Vol. 18 (4) , S176-S177
Phosphorylated Histone H3 (PHH3) is a novel, interesting prognostic marker in GEP-NETs
- 1 June 2018
- Published by Elsevier in Pancreatology
- Vol. 18 (4) , S176-S177
Phosphorylated Histone H3 (PHH3) is a novel, interesting prognostic marker in GEP-NETs
- 1 June 2018
- Published by Elsevier in Pancreatology
- Vol. 18 (4) , S129-S130
Presentation symptoms and risk factors are associated with diagnostic delay and disease stage but not with prognosis in PDAC patients
- 1 June 2018
- Published by Elsevier in Pancreatology
- Vol. 18 (4) , S129-S130
Presentation symptoms and risk factors are associated with diagnostic delay and disease stage but not with prognosis in PDAC patients
- 1 June 2018
- Published by Elsevier in Pancreatology
- Vol. 18 (4) , S107
Clinical and nutritional features are predictable for hospitalization in patients with Chronic Pancreatitis: a cohort study
- 1 June 2018
- Published by Elsevier in Pancreatology
- Vol. 18 (4) , S107
Clinical and nutritional features are predictable for hospitalization in patients with Chronic Pancreatitis: a cohort study
- 12 April 2018
- Published by Springer Nature
- p. 209-239
Molecular Pathology of Pancreatic Endocrine Tumors
- 12 April 2018
- Published by Springer Nature
- p. 209-239
Molecular Pathology of Pancreatic Endocrine Tumors
- 11 November 2017
- Published by Springer Nature
- p. 1-32
Molecular Pathology of Pancreatic Endocrine Tumors
- 11 November 2017
- Published by Springer Nature
- p. 1-32
Molecular Pathology of Pancreatic Endocrine Tumors
- 7 September 2017
- Published by Springer Nature
- p. 219-234
Therapy for Locoregional Disease: Stomach/Duodenum, Colon/Rectum
- 7 September 2017
- Published by Springer Nature
- p. 219-234
Therapy for Locoregional Disease: Stomach/Duodenum, Colon/Rectum
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S669
Heterogeneity of Type 1 Gastric Neuroendocrine Neoplasms
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S669
Heterogeneity of Type 1 Gastric Neuroendocrine Neoplasms
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S670
Type 3 Gastric Neuroendocrine Neoplasms: Relationship between Tumor Size, Ki67 and Clinical Outcome
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S670
Type 3 Gastric Neuroendocrine Neoplasms: Relationship between Tumor Size, Ki67 and Clinical Outcome